课题基金 / 基金详情

Discovery of novel Henipavirus inhibitors

Discovery of novel Henipavirus inhibitors
新型亨尼帕病毒抑制剂的发现
批准号:
10514154
负责人:
Thomas William Geisbert
金额:
$529.18万
依托单位国家:
美国
项目类别:
财政年份:
2022
资助国家:
美国
项目状态:
未结题
起止时间:
2022-05-16 至 2025-04-30

项目摘要

项目成果

Thomas William Geisbert的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
PROJECT 3 – ABSTRACT The goal of this project is to discover novel henipavirus inhibitors. Henipavirus is a deadly airborne respiratory pathogen that are under-researched and poorly understood. Antiviral therapy is urgently needed for henipaviruses for pandemic preparedness. We will achieve the goal by pursuing three aims. (i) Screen and identify novel compounds for Nipah and/or Hendra virus inhibition. Since Nipah and Hendra viruses should be handled at BSL4, it is challenging to perform high-throughput screen at high containment. To overcome this bottleneck, we will use a BSL2 Cedar henipavirus as a surrogate system for antiviral screen. Hits identified from the Cedar henipavirus assay will be validated in Hendra and Nipah viruses at the BSL4 facility. (ii) Develop tool compounds, determine target protein, and optimize molecules. (iii) Evaluate lead compounds in relevant in vitro and in vivo models and select Development Candidate for IND-enabling studies. The proposed cell-based approach may discover novel antiviral targets that may not be tractable for target-based antiviral approach.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Discovery of novel Henipavirus inhibitors
Preclinical development of a vaccine for Nipah virus
Preclinical development of a vaccine for Nipah virus
Preclinical development of a vaccine for Nipah virus
海外基金